Catabasis Pharmaceuticals has dosed the first patient as part of a part B of the MoveDMD trial, which is a 12-week study to assess the efficacy of CAT-1004 in Duchenne muscular dystrophy (DMD) disorder.

CAT-1004 is an inhibitor of NF-kB and an oral small-molecule. It could be a disease-modifying therapy for treatment of DMD, regardless of the underlying dystrophin mutation.

In animal models of DMD, CAT-1004 inhibited NF-kB, which is a protein activated in Duchenne and drives inflammation and fibrosis, muscle degeneration and suppresses muscle regeneration.

Catabasis is conducting the MoveDMD trial in two chronological parts, part A and part B.

"Catabasis has received positive biomarker results from part A of the MoveDMD trial, showing successful NF-kB target engagement."

During part A of the MoveDMD trial, 17 ambulatory boys between the age of four and seven with a genetically confirmed diagnosis of DMD across a range of dystrophin mutations received CAT-1004.

The boys were steroid naive or had not used steroids for at least six months prior to the trial. Part A was conducted at three sites in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial assessed the safety, tolerability and pharmacokinetics of CAT-1004 in patients at three dosing levels, which include 33mg/kg/day, 67mg/kg/day and 100mg/kg/day, during seven days of dosing.

Catabasis has received positive biomarker results from part A of the MoveDMD trial, showing successful NF-kB target engagement.

The biomarker assay piloted in boys affected by DMD demonstrated a statistical decrease in NF-kB gene expression markers compared to baseline at the 67mg/kg and 100mg/kg per day doses, as well as a statistically significant dose response in the gene expression data measured from whole blood samples.

Catabasis previously announced positive safety, tolerability and pharmacokinetics results from part A of the trial.

Part B the MoveDMD trial is a randomised, double-blind, placebo-controlled trial that will evaluate the safety and efficacy of CAT-1004 in DMD over a period of 12 weeks at five clinical trial sites in the US at two dosing levels, including 67mg/kg/day and 100mg/kg/day.

The boys who participated in part A of the MoveDMD trial are also expected to be involved in part B, with more participants expected to be enrolled for a total of around 30 boys.

Catabasis is currently identifying patients who are interested in participating in part B of the trial.